InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
4
T+90 hit rate
0%
T+90 mean return
-0.1%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by DOYLE WILLIAM F, Président Exécutif. Insider active across 2 companies, notably NovoCure Ltd. Aggregated, 11 disclosures have been logged. Split: 2 buys · 4 sells. Total volume traded: €920k. History available since 2 August 2021. The latest transaction was disclosed on 29 November 2024 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations11 total
18,169 shares0Common StockSEC:0001415889-24-028153:0
15,000 shares@ US$16.9851.2% of flowCommon StockSEC:0001415889-24-014279:0
Ideal exit: 15 Feb 2025 (T+270)
15,000 shares@ US$16.3048.8% of flowCommon StockSEC:0001415889-24-007635:0
Ideal exit: 3 Dec 2024 (T+270)
20,374 shares0Common StockSEC:0001415889-23-015780:0
18,649 shares0Common StockSEC:0001415889-22-011980:0
837 shares@ US$69.65912.4% of flowOrdinary SharesSEC:0001645113-22-000071:0
2,385 shares@ US$70.100.011% mcap38.1% of flowOrdinary SharesSEC:0001645113-22-000024:0
7,307 shares0Common StockSEC:0001179110-21-010527
7,307 shares0Common StockSEC:0001179110-21-010527:0
995 shares@ US$149.3780.0086% mcap31.0% of flowOrdinary SharesSEC:0001645113-21-000096:0
995 shares@ US$149.37827.1% of flowOrdinary SharesSEC:0001645113-21-000096
11 of 11 declarations
About DOYLE WILLIAM F
William F. Doyle is the Executive Chairman and Director at NovoCure Ltd and Elanco Animal Health Inc. In this role, he oversees board activities and contributes to the strategic direction of the companies. Doyle brings significant experience in leadership and management, helping to guide growth initiatives and ensure regulatory compliance. His commitment to operational excellence is an asset to the board.
